Inspire Medical Systems has been in a holding pattern, posting a small loss of 2.8% while floating around $183.55. The stock ...

Medical technology company Inspire Medical Systems (NYSE:INSP) reported Q4 CY2024 results , with sales up 24.5% year on year to $239.7 million. The company expects the full year’s revenue to be around ...

Learn more about whether Inspire Medical Systems, Inc. or NovoCure Limited is a better investment based on AAII's A+ Investor ...

Inspire Medical Systems is a leader in neurostimulation technology for obstructive sleep apnea; its devices are the only ones of their type with FDA approval. The company is now focused on ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service ...

Learn more about whether Inspire Medical Systems, Inc. or DENTSPLY SIRONA Inc. is a better investment based on AAII's A+ ...

Inspire Medical Systems reported strong Q4 results, achieving its first full year of profitability and setting ambitious targets for 2025. The upcoming full launch of Inspire V is a key growth ...

MINNEAPOLIS, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, ...

Inspire Medical Systems (NYSE:INSP – Free Report) had its price target trimmed by Morgan Stanley from $230.00 to $220.00 in a research note issued to investors on Tuesday,Benzinga reports.

Analysts' ratings for Inspire Medical Systems INSP over the last quarter vary from bullish to bearish, as provided by 4 analysts. Summarizing their recent assessments, the table below illustrates ...

Since August 2024, Inspire Medical Systems has been in a holding pattern, posting a small loss of 2.8% while floating around $183.55. The stock also fell short of the S&P 500’s 6.1% gain during ...

Medical technology company Inspire Medical Systems (NYSE:INSP) reported Q4 CY2024 results topping the market’s revenue expectations , with sales up 24.5% year on year to $239.7 million.